ABBKine’s Human Lipopolysaccharides (LPS) ELISA Kit (KTE62375): Precision Detection for Innate Immunity and Inflammation Research

Lipopolysaccharides (LPS), the major component of the outer membrane of Gram-negative bacteria, stands as a pivotal trigger of innate immune responses and a key biomarker for sepsis, inflammatory bowel disease, and chronic inflammatory disorders. Accurate quantification of LPS in human samples—from serum and plasma to tissue homogenates—has become indispensable for understanding disease pathogenesis, evaluating therapeutic efficacy, and advancing translational medicine. ABBKine, a trusted provider of high-performance biological research tools, addresses this critical need with its Human Lipopolysaccharides (LPS) ELISA Kit (Catalog No.: KTE62375), a product engineered to deliver exceptional specificity, reliability, and practicality. Built on a validated two-site sandwich ELISA platform, this kit redefines standards for LPS detection, offering researchers a robust solution to navigate the complexities of inflammatory and infectious disease research.

The foundation of the ABBKine Human Lipopolysaccharides (LPS) ELISA Kit’s superiority lies in its advanced two-site sandwich ELISA design, optimized specifically for human-derived LPS. Unlike conventional assays that struggle with cross-reactivity to bacterial fragments or host-derived molecules, this kit employs highly specific monoclonal antibodies that target conserved epitopes of human-relevant LPS. This design ensures that only intact LPS molecules are quantified, eliminating false positives caused by degraded bacterial components or non-specific binding to serum proteins. For researchers studying sepsis—where even minor inaccuracies in LPS detection can skew clinical relevance—this level of specificity is non-negotiable. It enables precise differentiation between true LPS-induced inflammation and secondary inflammatory responses, providing data that directly informs hypotheses about disease progression and therapeutic targets. Industry insights highlight that such specificity is increasingly critical as research shifts toward personalized medicine, where targeted biomarker quantification drives treatment decisions.

Beyond specificity, the Human Lipopolysaccharides (LPS) ELISA Kit (KTE62375) addresses a core industry challenge: balancing sensitivity with sample compatibility. LPS concentrations in human samples can vary drastically—from picogram levels in healthy individuals to microgram levels in severe sepsis. ABBKine’s kit is calibrated to detect LPS across a broad dynamic range, ensuring reliable quantification even in low-abundance samples without the need for extensive dilution or concentration steps. This versatility extends to sample types: the kit is validated for use with serum, plasma, and tissue homogenates, eliminating the need for multiple assays to analyze different sample matrices. For translational researchers working with clinical specimens, this means seamless integration of LPS data from patient blood draws and tissue biopsies, facilitating comprehensive disease profiling. The kit’s compatibility with standard laboratory equipment further enhances its utility, as it requires no specialized instrumentation, making advanced LPS detection accessible to both core facilities and small research labs.

Cost-effectiveness and scalability are key considerations in today’s research landscape, and the ABBKine Human Lipopolysaccharides (LPS) ELISA Kit delivers exceptional value at $359 for 48 tests. In an industry where specialized LPS assays often command prices upwards of $450–$600 for comparable formats, this pricing strategy democratizes access to high-quality detection tools. Critically, affordability does not compromise quality: ABBKine maintains strict batch-to-batch validation protocols, ensuring consistent sensitivity (limit of detection < 10 pg/mL, per typical performance benchmarks) and precision (intra-assay CV < 8%, inter-assay CV < 10%). This reliability is particularly valuable for large-scale studies—such as epidemiological surveys of LPS exposure or clinical trials of anti-inflammatory therapeutics—where consistent data across hundreds of samples is essential. For academic labs and early-stage biotechs operating on constrained budgets, the kit’s cost-performance ratio enables expanded sample sizes and more robust statistical analysis, accelerating research outcomes without sacrificing scientific rigor.

A defining strength of the Human Lipopolysaccharides (LPS) ELISA Kit (KTE62375) is its alignment with the evolving needs of inflammatory disease research. Industry trends indicate a growing focus on the role of LPS in chronic, low-grade inflammation—linked to conditions like obesity, type 2 diabetes, and cardiovascular disease—rather than just acute infections. This shift demands assays that can detect subtle changes in LPS levels over time, requiring long-term reproducibility and stability. ABBKine’s kit meets this demand with stable reagents and a streamlined protocol that minimizes pre-analytical variability. The kit’s detailed user manual provides clear guidance on sample collection, storage, and processing, reducing the risk of LPS degradation or contamination—common pitfalls that can compromise data integrity. For researchers investigating the link between gut microbiota-derived LPS and metabolic disorders, this level of procedural standardization ensures that results reflect true biological variation, not experimental error.

As the global burden of inflammatory and infectious diseases continues to rise, the demand for reliable LPS detection tools will only intensify. The ABBKine Human Lipopolysaccharides (LPS) ELISA Kit (KTE62375) stands out as a forward-thinking solution, combining technical excellence with practical design to address the most pressing challenges in the field. Its specificity for human LPS, broad sample compatibility, cost-effectiveness, and alignment with emerging research trends make it an indispensable tool for immunologists, microbiologists, and clinical researchers alike. Whether used to study sepsis pathogenesis, evaluate anti-LPS therapeutics, or explore the role of LPS in chronic inflammation, this kit empowers researchers to generate high-quality, actionable data.

To unlock the full potential of your inflammatory and infectious disease research, explore the ABBKine Human Lipopolysaccharides (LPS) ELISA Kit (KTE62375) in detail. Access comprehensive validation data, protocol resources, and technical support by visiting the official product page at https://www.abbkine.com/?s_type=productsearch&s=KTE62375. With ABBKine’s commitment to innovation and quality, this kit is more than a reagent—it is a catalyst for advancing our understanding of LPS-driven diseases and improving patient outcomes.